MSC-derived Extracellular Vesicles Attenuate Immune Responses in Two Autoimmune Murine Models: Type 1 Diabetes and Uveoretinitis. Academic Article uri icon

abstract

  • Accumulating evidence shows that extracellular vesicles (EVs) produced by mesenchymal stem/stromal cells (MSCs) exert their therapeutic effects in several disease models. We previously demonstrated that MSCs suppress autoimmunity in models of type 1 diabetes (T1D) and experimental autoimmune uveoretinitis (EAU). Therefore, here, we investigated the therapeutic potential of MSC-derived EVs using our established mouse models for autoimmune diseases affecting the pancreas and the eye: T1D and EAU. The data demonstrate that MSC-derived EVs effectively prevent the onset of disease in both T1D and EAU. In addition, the mixed lymphocyte reaction assay with MSC-derived EVs indicated that EVs inhibit activation of antigen-presenting cells and suppress development of T helper 1 (Th1) and Th17 cells. These results raise the possibility that MSC-derived EVs may be an alternative to cell therapy for autoimmune disease prevention.

published proceedings

  • Stem Cell Reports

altmetric score

  • 7.05

author list (cited authors)

  • Shigemoto-Kuroda, T., Oh, J. Y., Kim, D., Jeong, H. J., Park, S. Y., Lee, H. J., ... Lee, R. H

citation count

  • 147

complete list of authors

  • Shigemoto-Kuroda, Taeko||Oh, Joo Youn||Kim, Dong-Ki||Jeong, Hyun Jeong||Park, Se Yeon||Lee, Hyun Ju||Park, Jong Woo||Kim, Tae Wan||An, Su Yeon||Prockop, Darwin J||Lee, Ryang Hwa

publication date

  • May 2017